Earnings$ILMN4:05 PM ET9 wires · v9

Illumina beats Q3 earnings estimates, lifts full-year guidance on clinical demand and NovaSeq X placements

By BORSA NewsroomPublished Oct 29, 2026, 4:05 PM EDTUpdated Oct 29, 2026, 4:07 PM EDT

Illumina Q3 adjusted EPS $1.44 vs $1.36 estimate, revenue $1.13B vs $1.15B. Raised FY26 revenue and EPS guidance. Free cash flow $378M beat $223M estimate.

Sentimentbullish 85

Strongly bullish · 85 of 100

Impact70

medium · sector-wide

Confidence95%

high confidence · 9 wires

Eventconfirmed

v9 · alerted to followers

WHAT WE KNOW

Q3 2026 reported revenue $1.13B, up 4.2% YoY
Adjusted EPS $1.44 vs estimate $1.36